Treatment Patterns And Clinical Outcomes Among Patients Receiving Palbociclib Combinations For Hr+/her2- Advanced/Metastatic Breast Cancer In Real World Settings

Trial Profile

Treatment Patterns And Clinical Outcomes Among Patients Receiving Palbociclib Combinations For Hr+/her2- Advanced/Metastatic Breast Cancer In Real World Settings

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Palbociclib (Primary) ; Fulvestrant; Letrozole
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms IRIS
  • Sponsors Pfizer
  • Most Recent Events

    • 05 Jun 2018 Results of women who had failed endocrine therapy in adjuvant settings (n= 652 ) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2018 Results (n=162) assessing treatment patterns and clinical outcomes associated with palbociclib combination therapy in Argentina, were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 24 Jul 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top